Familial Kidney Cancer: Implications of New Syndromes and Molecular Insights

Abstract

<div class="section"> <a class="named-anchor" id="S1"> <!-- named anchor --> </a> <h5 class="title" id="d817186e297">Context:</h5> <p id="P13">Hereditary cases account for about 5% of all cases of renal cell carcinoma (RCC). With advances in next-generation sequencing, several new hereditary syndromes have been described in the last few years. </p> </div><div class="section"> <a class="named-anchor" id="S2"> <!-- named anchor --> </a> <h5 class="title" id="d817186e302">Objective:</h5> <p id="P14">To review and summarise the recent preclinical and clinical literature in hereditary renal cancer. </p> </div><div class="section"> <a class="named-anchor" id="S3"> <!-- named anchor --> </a> <h5 class="title" id="d817186e307">Evidence acquisition:</h5> <p id="P15">A systematic review of the literature was performed in November 2018 using PubMed and OMIM databases, with an emphasis on kidney cancer, genetics and genomics, clinical criteria, and management. </p> </div><div class="section"> <a class="named-anchor" id="S4"> <!-- named anchor --> </a> <h5 class="title" id="d817186e312">Evidence synthesis:</h5> <p id="P16">Several autosomal dominant hereditary RCC syndromes have been described, including those related to germline pathogenic variants in <i>VHL, MET, FH, TSC1/TSC2, FLCN, SDHA/B/C/D, BAP1, CDC73</i>, and <i>MITF</i>. Clinical spectrum of <i>SDH, BAP1</i>, and <i>MITF</i> is still being defined, although these appear to be associated with a lower incidence of RCC than the former. <i>FH</i> and likely <i>BAP1</i> RCC are associated with more aggressive disease. Preclinical and clinical studies show that using systemic therapy that exploits specific genetic pathways is a promising strategy. </p> </div><div class="section"> <a class="named-anchor" id="S5"> <!-- named anchor --> </a> <h5 class="title" id="d817186e336">Conclusions:</h5> <p id="P17">There are several well-described hereditary RCC syndromes, as well as recently identified ones, for which the full clinical spectrum is yet to be defined. In the new era of precision medicine, identification of these syndromes may play an important role in management and systemic treatment selection. </p> </div><div class="section"> <a class="named-anchor" id="S6"> <!-- named anchor --> </a> <h5 class="title" id="d817186e341">Patient summary:</h5> <p id="P18">This review covers updates in the diagnosis and management of familial kidney cancer syndromes. We describe updates in testing and management of the most common syndromes such as von Hippel-Lindau, and hereditary leiomyomatosis and renal cell carcinoma. We also provide insights into recently described familial kidney cancer syndromes. </p> </div>